Position in JANX
as of Mar 31, 2026
· filed Apr 27, 2026
Position Value
$469,486
-$414,017 QoQ
Shares Held
33,776
-47.2% QoQ
Ownership
0.055%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in JANX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026PROFUND ADVISORS LLC holds $183,565,563 across 158 Biotechnology names. JANX ranks #99 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
23,137 | $10,331,595 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
10,332 | $7,982,916 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
14,647 | $4,846,252 | |
| 4 | INSM |
INSMED Inc
|
27,937 | $4,568,258 | |
| 5 | APLS |
Apellis Pharmaceuticals, Inc.
|
81,190 | $3,266,273 | |
| 6 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
4,862 | $2,545,111 | |
| 7 | TGTX |
Tg Therapeutics, Inc.
|
76,039 | $2,526,015 | |
| 8 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
39,758 | $2,492,826 |
All Filings in JANX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $469,486 | 33,776 | Shares | Sole | 2026-04-27 | |
| 2025-12-31 | $883,503 | 64,022 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $401,744 | 16,438 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $232,201 | 10,052 | Shares | Sole | 2025-08-07 | |
| 2025-03-31 | $316,602 | 11,726 | Shares | Sole | 2025-05-08 | |
| 2024-12-31 | $546,429 | 10,206 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $591,135 | 13,012 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $597,937 | 14,274 | Shares | Sole | 2024-08-13 | |
| No filing history on record for this holder in this stock. | ||||||